Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1306
- Registration Number
- NCT00327015
- Locations
- 🇺🇸
Newark Physician Associates, Newark, Ohio, United States
🇺🇸East Bay Clinical Trial Center, Concord, California, United States
🇺🇸Community Clinical Trials, Orange, California, United States
Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 365
- Registration Number
- NCT00316082
- Locations
- 🇺🇸
Southland Clinical Research Center, Inc., Fountain Valley, California, United States
🇺🇸Winston Technology, Inc., Haleyville, Alabama, United States
🇺🇸Clinical Reseacrh Advantage/ Brown Family Medicine, Mesa, Arizona, United States
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 768
- Registration Number
- NCT00313313
- Locations
- 🇺🇸
Stewart Medical Group, Alhambra, California, United States
🇺🇸Valley Research, Fresno, California, United States
🇺🇸Randall Shue, D.O., Los Angeles, California, United States
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 565
- Registration Number
- NCT00295633
- Locations
- 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸Mouhaffel, Assad H., West Monroe, Louisiana, United States
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT00121641
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.